Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population. The Food and Drug ...

University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.” The conference will take place online and ...

The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals when used alongside stereotactic body radiotherapy (SBRT), a focused form of ...

A molecular imaging tool developed by researchers at the University of California’s two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer ...

A panel of experts offers guidance for selecting patients with mCRPC for treatment with 177Lu-PSMA-617 and for managing treatment-related toxicities. The treatment is approved for use in men with ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should ...